Non-members: Click here to review a complimentary excerpt from "Resourcing a Successful Product Launch: Staffing Allocations"
The biopharmaceutical launch landscape is characterized by growing competition in the market and tighter resources for pre-launch activities. Launching a new product in such a complex environment requires meticulous resource planning from the pre-launch phase to beyond market entry.
To help biopharma leaders develop competitive staffing targets for launch and pre-launch activities, Best Practices, LLC conducted benchmarking research that probed current staffing allocations across the key activities required for a successful drug launch.
In particular, the study benchmarks the FTE allocation for 12 key promotional, educational and market-access activities for the launch year and the three years preceding launch. The study also assesses the investment ratios by FTEs and outlines the success factors for launching a new pharmaceutical product.
Launch and brand leaders can use this research to compare their staffing levels for pre-launch and launch activities with current benchmark from industry peers.
This study includes staffing segments for: Peak revenue; drug type; launch year; product position; and oncology therapeutic area.
- Launch Staffing Allocations
- Success Factors
- Staffing Investment Ratios
SAMPLE KEY METRICS
- Indicate the number of FTEs allocated for activities in 12 categories for the Launch Year and the three years preceding launch
- Indicate the launch spend per FTE for products with projected peak revenue of less than $1 Billion
SAMPLE KEY FINDING
- Among all the listed activities, sales field force activities receive highest staffing during launch year and launch year -1.
- Sixty-four percent of the benchmark participants consider market access and reimbursement as the most important success factor in establishing and allocating new product launch budgets.
This research engaged 34 marketing & commercial leaders from 27 leading pharmaceutical, biotech, and life sciences companies. Eleven study participants represent large pharma organizations, while the remaining benchmark class represent medium or small companies.